Forecasting Health Assessment

18 months following a $20B acquisition, numerous accounting and planning system integrations, higher than normal turnover and new ways of viewing financial data, the Corporate FP&A team wanted to step-back and ask how the forecast process was going.  Specifically, what was working well, what were the main points to use as a basis for improvement and to ensure the forecasting process was aligned with the business objectives and decision making. To help this, they used an outside consultant for a quick 3-week project.  This discussion will focus on the framework and process used to collect, analyze and prepare an action plan on the Genzyme global corporate planning processes. 

Michael biddlecom
Michael Biddlecom
Director, Finance
Mike Biddlecom is the Director, Corporate & U.S. Financial Planning and Analysis for Genzyme and is based in Cambridge, MA.  Since joining in June 2012, he leads the team responsible for the global consolidation of the Genzyme financials, planning processes, management reporting and oversight of BI tools. Prior to Genzyme, Mike spent over 10 years at Biogen Idec providing financial decision support and corporate alliances leadership across early stage R&D through commercial products.  He also supported three specialty sales forces with commercial analytics leadership. Michael holds a BS in Chemical Engineering from Bucknell University and an MBA from the Kellogg Graduate School of Management at Northwestern University.

Interested in more ondemand presentations?

Subscribe to ieOnDemand
Financial health small

Read next:

What Does The Finance Function At A Non-Profit Look Like?